查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1611998

皮质类固醇抑制剂市场：按药物、治疗类型、分销管道和最终用户划分 - 全球预测 2025-2030

Adrenal Corticosteroid Inhibitors Market by Drug (Aminoglutethimide, Levoketoconazole, Metyrapone), Treatment Type (Breast Cancer, Cushing's Syndrome, Prostate Cancer), Distribution Channel, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

皮质类固醇抑制剂市场2023年估值为24.9亿美元，预计到2024年将达到28亿美元，复合年增长率为12.75%，到2030年达到57.8亿美元。

皮质类固醇抑制剂是一种旨在抑制肾上腺产生的皮质类固醇的合成和作用的药物，主要用于治疗库欣氏症候群和肾上腺皮质荷尔蒙分泌过多等疾病。对这些抑制剂的需求源于它们平衡荷尔蒙水平和缓解与皮质醇过度产生相关的症状的能力。它的应用扩展到内分泌学，对于管理荷尔蒙失衡和治疗对标准治疗方法无反应的严重和难治性疾病至关重要。最终用途范围主要包括医疗部门，如医院、专科诊所、临床研究机构。根据市场洞察，肾上腺相关疾病盛行率的增加以及意识和诊断能力的提高正在推动市场的强劲成长轨迹。此外，药理学的进步刺激了研究并导致了更有效和更有针对性的抑制剂的开发。新兴市场充满机会，医疗保健基础设施不断扩大，知名度不断提高。对于希望利用这一机会的公司来说，策略重点是开发新颖的递送机制，例如缓释性，可以使他们的产品在竞争格局中脱颖而出。然而，由于严格的法规环境、高昂的药物开发成本以及可能抑制患者依从性的潜在副作用，该市场面临限制。肾上腺疾病的复杂性也对准确诊断和治疗效果提出了挑战。个人化医疗的创新、利用遗传洞察来客製化抑制剂概况以及生物技术和製药公司之间加强合作可以推动业务的显着成长。该市场以成长为导向，但也很谨慎，对于那些能够预测不断变化的监管条件、快速适应并投资于尖端研究和以患者为中心的解决方案的公司来说，这是最好的机会。能够克服这些障碍的公司将能够获得竞争优势，并为不断发展的治疗领域做出贡献。

主要市场统计
基准年[2023] 24.9亿美元
预测年份 [2024] 28亿美元
预测年份 [2030] 57.8亿美元
复合年增长率（%） 12.75%

市场动态：快速发展的皮质类固醇抑制剂市场的关键市场洞察

供需的动态交互作用正在改变皮质类固醇抑制剂市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 治疗内分泌疾病对皮质类固醇抑制剂的需求不断增加
    • 政府对基于皮质类固醇抑制剂的药物的核准增加
  • 市场限制因素
    • 皮质类固醇抑制剂认知度低且成本高
  • 市场机会
    • 大量投资皮质类固醇抑制剂的研发
    • 先进医疗设施的不断增加和製药领域的进步
  • 市场挑战
    • 对基于皮质类固醇抑制剂的药物副作用的担忧

波特的五力：驾驭皮质类固醇抑制剂市场的策略工具

波特的五力框架是了解皮质类固醇抑制剂市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解皮质类固醇抑制剂市场的外部影响

外部宏观环境因素在塑造皮质类固醇抑制剂市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解皮质类固醇抑制剂市场的竞争格局

对皮质类固醇抑制剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵皮质类固醇抑制剂市场供应商的绩效评估

FPNV定位矩阵是评估皮质类固醇抑制剂市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，绘製皮质类固醇抑制剂市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，皮质类固醇抑制剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 治疗内分泌疾病对皮质类固醇抑制剂的需求不断增加
      • 政府对基于皮质类固醇抑制剂的药物的核准增加
    • 抑制因素
      • 与皮质类固醇抑制剂相关的认知度低且成本高
    • 机会
      • 大量投资皮质类固醇抑制剂的研发
      • 先进医疗设施的增加和製药业的进步
    • 任务
      • 对基于皮质类固醇抑制剂的药物副作用的担忧
  • 市场区隔分析
    • 药物：奥西洛司他药物的使用激增作为疾病的长期治疗选择
    • 治疗类型：增加皮质类固醇抑制剂的使用来治疗库欣氏症候群
    • 交付管道：不断发展的皮质类固醇抑制剂线上交付管道
    • 最终用户：专门中心大量采用皮质类固醇抑制剂
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章皮质类固醇抑制剂市场（依药物）

  • 胺基
  • Ketoconazole
  • 甲吡酮
  • 示波器

第七章依治疗类型分類的皮质类固醇抑制剂市场

  • 乳癌
  • 库欣氏症候群
  • 摄护腺癌

第八章皮质类固醇抑制剂市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章皮质类固醇抑制剂市场：依最终用户分类

  • 医院
  • 专业中心

第十章北美和南美皮质类固醇抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区皮质类固醇抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲皮质类固醇抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Coherus 和君实生物科技宣布 FDA核准LOQTORZI（特瑞普利单抗-tpzi）用于所有復发性或转移性鼻咽癌 (NPC) 治疗线
    • 美国FDA核准双效锭剂AKEEGA（尼拉帕尼和Abiraterone龙）用于治疗 BRCA 阳性转移性去势抗性前列腺癌患者
    • Moderna 和默克公司宣布，临床实验个人化 mRNA 癌症疫苗 mRNA-4157/V940 与 KEYTRUDA®（ Pembrolizumab ）联合使用在 2b 期 KEYNOTE-942 研究中达到了主要疗效终点
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Adooq Bioscience LLC
  • Cayman Chemical Company
  • Crinetics Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Enzo Life Sciences, Inc.
  • Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
  • HRA Pharma Rare Diseases SAS by Perrigo Company plc
  • MedChemExpress
  • Merck KGaA
  • Novartis AG
  • Orphagen Pharmaceuticals
  • Pfizer Inc.
  • Sparrow Pharmaceuticals Inc.
  • Steris Healthcare PVT Ltd
  • Tocris Bioscience by Bio-Techne Corporation
  • Xeris Biopharma Holdings, Inc.
Product Code: MRR-FB6C9E792FB6

The Adrenal Corticosteroid Inhibitors Market was valued at USD 2.49 billion in 2023, expected to reach USD 2.80 billion in 2024, and is projected to grow at a CAGR of 12.75%, to USD 5.78 billion by 2030.

Adrenal Corticosteroid Inhibitors are pharmaceutical agents designed to block the synthesis and effects of corticosteroids produced in the adrenal gland, primarily aimed towards conditions like Cushing's syndrome or hypercortisolism. The necessity of these inhibitors arises from their ability to balance hormone levels and alleviate symptoms associated with excessive cortisol production. Their application extends to endocrinology, being crucial for managing hormonal imbalances, and they are pivotal for treating severe refractory conditions that do not respond to standard therapies. The end-use scope predominantly includes health sectors such as hospitals, specialty clinics, and clinical research institutions. Market insights reveal a robust growth trajectory driven by an increase in the prevalence of adrenal-related disorders coupled with greater awareness and diagnostic capabilities. Furthermore, advancements in pharmacology have stimulated research, leading to the development of more potent and targeted inhibitors. Opportunities are abound in emerging markets where healthcare infrastructure is expanding, and awareness is rising. For companies looking to capitalize, a strategic focus on the development of novel delivery mechanisms, such as extended-release formulations, can differentiate offerings in a competitive landscape. However, the market faces limitations due to stringent regulatory environments, high costs of drug development, and potential side effects, which can obstruct patient compliance. The complex nature of adrenal disorders also suggests challenges in accurate diagnosis and treatment efficacy. Innovating in personalized medicine, leveraging genetic insights to tailor inhibitor profiles, and enhancing collaboration between biotech and pharmaceutical companies can foster significant business growth. The market tends towards a growth-oriented but cautious landscape, with opportunities best captured by those who anticipate regulatory changes, adapt promptly, and invest in cutting-edge research and patient-centric solutions. Companies able to navigate through these barriers will likely achieve competitive advantage and contribute to the evolving therapeutic landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 2.49 billion
Estimated Year [2024] USD 2.80 billion
Forecast Year [2030] USD 5.78 billion
CAGR (%) 12.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adrenal Corticosteroid Inhibitors Market

The Adrenal Corticosteroid Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing need for adrenal corticosteroid inhibitors to treat endocrine diseases
    • Rising government approvals for adrenal corticosteroid inhibitors-based drugs
  • Market Restraints
    • Limited awareness and high cost associated with adrenal corticosteroid inhibitors
  • Market Opportunities
    • Significant investments in research and development of adrenal corticosteroid inhibitors
    • Growing presence of refined medical facilities and advances in pharmaceutical sector
  • Market Challenges
    • Concerns regarding side impacts of adrenal corticosteroid inhibitors-based drugs

Porter's Five Forces: A Strategic Tool for Navigating the Adrenal Corticosteroid Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adrenal Corticosteroid Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adrenal Corticosteroid Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adrenal Corticosteroid Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adrenal Corticosteroid Inhibitors Market

A detailed market share analysis in the Adrenal Corticosteroid Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adrenal Corticosteroid Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adrenal Corticosteroid Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adrenal Corticosteroid Inhibitors Market

A strategic analysis of the Adrenal Corticosteroid Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adrenal Corticosteroid Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adooq Bioscience LLC, Cayman Chemical Company, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Enzo Life Sciences, Inc., Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., HRA Pharma Rare Diseases SAS by Perrigo Company plc, MedChemExpress, Merck KGaA, Novartis AG, Orphagen Pharmaceuticals, Pfizer Inc., Sparrow Pharmaceuticals Inc., Steris Healthcare PVT Ltd, Tocris Bioscience by Bio-Techne Corporation, and Xeris Biopharma Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Adrenal Corticosteroid Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Aminoglutethimide, Levoketoconazole, Metyrapone, and Osilodrostat.
  • Based on Treatment Type, market is studied across Breast Cancer, Cushing's Syndrome, and Prostate Cancer.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End-user, market is studied across Hospitals and Speciality Centres.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing need for adrenal corticosteroid inhibitors to treat endocrine diseases
      • 5.1.1.2. Rising government approvals for adrenal corticosteroid inhibitors-based drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and high cost associated with adrenal corticosteroid inhibitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant investments in research and development of adrenal corticosteroid inhibitors
      • 5.1.3.2. Growing presence of refined medical facilities and advances in pharmaceutical sector
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding side impacts of adrenal corticosteroid inhibitors-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases
    • 5.2.2. Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome
    • 5.2.3. Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors
    • 5.2.4. End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Adrenal Corticosteroid Inhibitors Market, by Drug

  • 6.1. Introduction
  • 6.2. Aminoglutethimide
  • 6.3. Levoketoconazole
  • 6.4. Metyrapone
  • 6.5. Osilodrostat

7. Adrenal Corticosteroid Inhibitors Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Cushing's Syndrome
  • 7.4. Prostate Cancer

8. Adrenal Corticosteroid Inhibitors Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Adrenal Corticosteroid Inhibitors Market, by End-user

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Speciality Centres

10. Americas Adrenal Corticosteroid Inhibitors Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Adrenal Corticosteroid Inhibitors Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Adrenal Corticosteroid Inhibitors Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
    • 13.3.2. U.S. FDA Approves AKEEGA (Niraparib and Abiraterone Acetate), the Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
    • 13.3.3. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adooq Bioscience LLC
  • 3. Cayman Chemical Company
  • 4. Crinetics Pharmaceuticals, Inc.
  • 5. Eli Lilly and Company
  • 6. Enzo Life Sciences, Inc.
  • 7. Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
  • 8. HRA Pharma Rare Diseases SAS by Perrigo Company plc
  • 9. MedChemExpress
  • 10. Merck KGaA
  • 11. Novartis AG
  • 12. Orphagen Pharmaceuticals
  • 13. Pfizer Inc.
  • 14. Sparrow Pharmaceuticals Inc.
  • 15. Steris Healthcare PVT Ltd
  • 16. Tocris Bioscience by Bio-Techne Corporation
  • 17. Xeris Biopharma Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ADRENAL CORTICOSTEROID INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ADRENAL CORTICOSTEROID INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADRENAL CORTICOSTEROID INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY AMINOGLUTETHIMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY LEVOKETOCONAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY METYRAPONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY OSILODROSTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. ADRENAL CORTICOSTEROID INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. ADRENAL CORTICOSTEROID INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023